Combined entity delivers the ICyte®
revenue optimization platform powered by first-party data,
AI-enabled data exploration, and field intelligence and
alerting
PHILADELPHIA, June 18,
2024 /PRNewswire/ -- IntegriChain, delivering
pharma's comprehensive technology, data, consulting, and
outsourcing platform for data-driven commercialization, today
announced the acquisition of BridgeView Data Solutions, the
commercial data warehouse and data aggregation assets of BridgeView
Life Sciences LLC (formerly Coeus Solutions). This transaction
allows IntegriChain and BridgeView to offer pharmaceutical
manufacturers best-in-class first- and third-party data
aggregation, add AI-assisted data exploration capabilities, extend
its reach through field intelligence and alerting, deliver new
commercial data warehouse (CDW) offerings, and deepen its strength
in commercial data strategy.
"Pharma is under pressure to improve profitability like never
before," said Josh Halpern, CEO of
IntegriChain. "Legacy commercial strategies and commercial decision
support have resulted in an industry outlook of flat to down net
revenue. To return to profitable growth, manufacturers need to
connect the back and front of the house – starting with their
commercial, financial, and operational data. We are thrilled to
join forces with BridgeView Data Solutions to deliver the Pharma
industry's first platform that meets the needs of the Pharma
industry by integrating all the third-party and first-party data
that drive both commercial execution and the net revenue cycle.
Together, we will deliver analytics that can transform the
bottom-line impact of access, affordability, patient service,
channel, and field investments. For IntegriChain, this is a very
synergistic sixth acquisition – and the first following our
partnership with Nordic Capital – as we execute on our ambitious
growth targets and help pharma manufacturers bring their science to
market."
"High quality first-party data – especially first-party
patient-level data – is increasingly essential to day-to-day
commercial and operational execution. More and more use cases
require commercial first- and third-party data to flow back into
net revenue business processes, and net revenue first party data to
flow forward into commercial decisioning," said Mike Zubey, CEO of BridgeView Life Sciences.
"IntegriChain has established itself as an innovator in net revenue
optimization. We are excited to join IntegriChain's family and
platform, and to be an integral part of embedding our combined
capabilities in pharma's commercial execution."
Combined Data Offerings
IntegriChain will offer BridgeView's DataBridge™ commercial data
warehouse, delivering a flexible, scalable platform for data
synthesis, enrichment, and application. DataBridge ingests, stores,
governs, and analyzes data from heterogeneous sources, including
existing databases, business applications, and industry-standard
solutions. By harmonizing and enriching disparate information
flows, DataBridge equips commercial stakeholders with the right
insights faster through accurate ad-hoc analysis, rapid BI
reporting, and advanced data science enabled by AI/ML technology.
IntegriChain will provide connectivity between its ICyte net
revenue optimization platform and DataBridge to drive profitable
insights for manufacturers.
IntegriChain will integrate key features of BridgeView's
specialty data aggregation platform into ICyte Patient Data
Solutions. BridgeView's AI-powered data exploration and field
intelligence and patient journey alerting – via popular CRM systems
including Veeva Vault CRM Suite – perfectly complement
IntegriChain's ICyte patient mastering and patient journey
analytics to deliver best-in-class data aggregation to the Pharma
industry.
Under terms of the agreement, IntegriChain acquired all data
solutions assets of BridgeView Life Sciences, LLC. The entire Data
Solutions leadership and professional team will join IntegriChain's
global workforce that spans nearly 750 professionals. BridgeView
customers should expect no changes or interruptions to the delivery
of their solutions and servicing of their accounts. This
acquisition is IntegriChain's sixth expansion and the first since
entering its strategic partnership in 2023 with Nordic Capital, a
leading sector-specialized private equity investor with a broad
portfolio in Healthcare, Pharma, and Technology.
About IntegriChain
IntegriChain helps pharma
manufacturers bring their science to market, ensuring patients have
affordable, timely, and sustainable access to therapy. IntegriChain
delivers Pharma's only data-driven commercialization platform —
from strategy to operational execution. The Company's unique focus
on data, technology, consulting, and outsourcing helps connect the
commercial, financial, and operational dimensions of drug access
and profitability. Through the ICyte Platform, IntegriChain enables
pharmaceutical innovators to achieve better commercial outcomes by
digitalizing daily and recurring business activities and by
integrating data and operations across contracting, pricing,
channel and distribution, and gross-to-net. IntegriChain is backed
by Nordic Capital, a leading sector-specialized private equity
investor with a broad portfolio in Healthcare and Technology, and
is headquartered in Philadelphia,
PA, with offices in Ambler,
PA, and Pune, India. For
more information, visit www.integrichain.com or follow on
LinkedIn.
Contact
Jennifer
Guinan, Sage Strategic Marketing, jennifer@sagestrat.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/integrichain-acquires-bridgeview-data-solutions-creating-the-pharmaceutical-industrys-best-in-class-commercial-data-solution-302176076.html
SOURCE IntegriChain